TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7798858

Group type: EXPERIMENTAL
Intervention: 2‐minute double freeze
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 3‐minute double freeze
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 5‐minute single freeze
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 5‐minute double freeze
Number of subjects: 70
Study: 3195756

Group type: EXPERIMENTAL
Intervention: Higher concentration of anesthetic plus phenylephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Light anesthesia to maintain similar systolic blood pressures and stump pressures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 60
Study: 30972657

Group type: EXPERIMENTAL
Intervention: Racemic amphetamine sulfate (RA-AMPH)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 28550071

Group type: EXPERIMENTAL
Intervention: Tubular discectomy
Number of subjects: 325

Group type: COMPARATOR
Intervention: Conventional microdiscectomy
Number of subjects: 325
Study: 25521304

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rupatadine
Number of subjects: 100
Study: 22251553

Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 18

Group type: COMPARATOR
Intervention: CT
Number of subjects: 18
Study: 21114690

Group type: EXPERIMENTAL
Intervention: Coated fatty acid supplementation (0.25% caprylic and capric acid, 1:1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Non-coated fatty acid supplementation (0.25% caprylic and capric acid, 1:1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coated fatty acid supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-coated fatty acid supplementation
Number of subjects: 48
Study: 17569583

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (SP) loading (1g of tribasic dodecahydrate sodium phosphate, four times daily for 6 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 6
Study: 16958396

Group type: EXPERIMENTAL
Intervention: Protocol of 150 ml of 300 mg I/ml
Number of subjects: 5

Group type: COMPARATOR
Intervention: Protocol of 100 ml of 300 mg I/ml
Number of subjects: 5

Group type: COMPARATOR
Intervention: Protocol of 100 ml of 350 mg I/ml
Number of subjects: 5
Study: 12712353

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the motor nerve
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Percutaneous electrical stimulation over the muscle belly
Number of subjects: 8
Study: 11129986

Group type: EXPERIMENTAL
Intervention: Neoadjuvant tamoxifen (20 mg/day for 3 weeks)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (matched patients)
Number of subjects: 107
Study: 9065902

Group type: EXPERIMENTAL
Intervention: GnRH agonist treatment (triptorelin) for 6 months
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MR-ELL method
Number of subjects: 27

Group type: COMPARATOR
Intervention: US-ELL measurements
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Myoma SI patterns
Number of subjects: 27

Group type: COMPARATOR
Intervention: MR and US comparison
Number of subjects: 27
Study: 1640278

Group type: EXPERIMENTAL
Intervention: Heparin (1/2 unit per milliliter of continuous intravenous infusate or intermittent heparin flush)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No heparin (control group)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 113
Study: 6713092

Group type: EXPERIMENTAL
Intervention: Myeloma morphology score (MMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myeloma progression score (MPS)
Number of subjects: 0
Study: 29798783

Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Minimally interrupted apixaban
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: All apixaban patients combined
Number of subjects: 306

Group type: COMPARATOR
Intervention: Matched warfarin group
Number of subjects: 306
Study: 26781590

Group type: EXPERIMENTAL
Intervention: Positive Action (PA) program
Number of subjects: 1170
Study: 25594919

Group type: EXPERIMENTAL
Intervention: Adding pharmacists to primary care teams
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 123
Study: 23080378

Group type: EXPERIMENTAL
Intervention: Quitline-based counseling intervention (CI) with up to 4 proactive telephone counseling sessions
Number of subjects: 410

Group type: COMPARATOR
Intervention: Self-help (SH) group receiving only mailed cessation materials
Number of subjects: 410
Study: 20945827

Group type: EXPERIMENTAL
Intervention: Personalized care condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care condition
Number of subjects: 60
Study: 18371480

Group type: EXPERIMENTAL
Intervention: Smoking (current smokers)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 803

Group type: COMPARATOR
Intervention: Age group comparison (18 to < 45 years vs > or = 45 years)
Number of subjects: 803
Study: 16617225

Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL) rehabilitation program, 1-year duration, 13 sessions in small groups
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 207
Study: 12866653

Group type: EXPERIMENTAL
Intervention: Lactate-buffered CVVH (treatment A)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bicarbonate-buffered CVVH (treatment B)
Number of subjects: 8
Study: 10989857

Group type: EXPERIMENTAL
Intervention: 15 microg clonidine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 30 microg clonidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0 microg clonidine (C0)
Number of subjects: 48
Study: 9298044

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Office (manual) measurement
Number of subjects: 70
Study: 8430965

Group type: EXPERIMENTAL
Intervention: Troleandomycin (TAO) combined with methylprednisolone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Methylprednisolone alone (placebo)
Number of subjects: 75
Study: 3511776

Group type: EXPERIMENTAL
Intervention: 4 mg albuterol
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 6 mg albuterol
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 29170875

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 212

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 212
Study: 26862930

Group type: COMPARATOR
Intervention: Triple therapy with esomeprazole (20 mg), amoxicillin (1000 mg), and clarithromycin (500 mg) twice daily for 7 days
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Sequential therapy with 5 days of esomeprazole (20 mg) and amoxicillin (1000 mg) twice daily, followed by 5 days of esomeprazole (20 mg), clarithromycin (500 mg) and metronidazole (400 mg) twice daily
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Concomitant therapy with esomeprazole (20 mg), amoxicillin (1000 mg), clarithromycin (500 mg) and metronidazole (400 mg) twice daily for 7 days
Number of subjects: 356
Study: 25157002

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 23255054

Group type: EXPERIMENTAL
Intervention: Care management intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 21917187

Group type: EXPERIMENTAL
Intervention: One-to-one peer support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group reminiscence programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-to-one peer support and group reminiscence combined
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18251659

Group type: EXPERIMENTAL
Intervention: Standard-of-care antimicrobial therapy after surgical incision and drainage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo after surgical incision and drainage
Number of subjects: 0
Study: 16482080

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g per day for 7 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both groups (Vitamin C and Placebo)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 7
Study: 14605529

Group type: EXPERIMENTAL
Intervention: Recruitment maneuvers (RMs) using continuous positive airway pressure of 35-40 cm H2O for 30 secs
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham recruitment maneuvers
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Recruitment maneuvers (RMs)
Number of subjects: 72
Study: 11038990

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied to points: Touwei (ST 8), Xuanlu (GB 5), Fengchi (GB 20), Dazhui (GV 14), Lieque (LU 7), treated with the reducing method.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional drug therapy (CDTG)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 120
Study: 8847442

Group type: EXPERIMENTAL
Intervention: Spontaneous obstructive apneas with hypoxemia
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Induced hypoxemia (1-4 breaths of 100% nitrogen)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Spontaneous obstructive apneas while breathing 100% oxygen (apnea without hypoxemia)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperoxic spontaneous obstructive apneas
Number of subjects: 9

Group type: COMPARATOR
Intervention: Induced hypoxemia in control subjects
Number of subjects: 9
Study: 1577051

Group type: EXPERIMENTAL
Intervention: Single dose omeprazole (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Short-term omeprazole treatment (20 mg/day for 8 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study: 3086177

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31536624

Group type: EXPERIMENTAL
Intervention: IVM annually at 0, 12, and 24 months
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: IVM semiannually at 0, 6, 12, 18, and 24 months
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: IVM+ALB annually
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: IVM+ALB semiannually
Number of subjects: 272

Group type: COMPARATOR
Intervention: IVM annually
Number of subjects: 272

Group type: COMPARATOR
Intervention: IVM semiannually
Number of subjects: 272
Study: 30064027

Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTF) therapy
Number of subjects: 1
Study: 27587614

Group type: EXPERIMENTAL
Intervention: EPIQ intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Booster intervention
Number of subjects: 16
Study: 24627569

Group type: EXPERIMENTAL
Intervention: Atenolol treatment for 9 weeks
Number of subjects: 234
Study: 22190354

Group type: EXPERIMENTAL
Intervention: Care management intervention
Number of subjects: 229
Study: 20823377

Group type: EXPERIMENTAL
Intervention: Theobromine-enriched cocoa (979 mg of theobromine)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Natural dose theobromine cocoa (106 mg of theobromine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 18565218

Group type: EXPERIMENTAL
Intervention: Absolute risk reduction (ARR)
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Relative risk reduction (RRR)
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Number needed to treat (NNT)
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Prolongation of life (POL) without heart attack
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: All four formats combined with pictorial representation
Number of subjects: 1169
Study: 18851773

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Applied relaxation (AR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed treatment (DT)
Number of subjects: 50
Study: 14643169

Group type: EXPERIMENTAL
Intervention: 12 microg formoterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: 18 microg tiotropium
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 12 microg formoterol + 18 microg tiotropium
Number of subjects: 20
Study: 11522234

Group type: COMPARATOR
Intervention: CD56(+) cell expandability before CT1 and CT2
Number of subjects: 18

Group type: COMPARATOR
Intervention: CD56(+) cell expandability after CT2 and G-CSF application
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CD56(+) cell expandability after PBSC harvesting before CT3 and HDCT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CD56(+) cell expandability two weeks after autografting
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CD56(+) cell expandability after recovery from autografting
Number of subjects: 18
Study: 9590461

Group type: EXPERIMENTAL
Intervention: 1.5 mg compressed tablet (CT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3.0 mg sustained release (SR) tablet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8145983

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 2
Study: 3197978

Group type: EXPERIMENTAL
Intervention: Basal diet with one dose of 90 g corn oil after the last meal (120 g fat/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Basal low fat diet containing 30 g of fat per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Basal diet with doses of 30 g corn oil taken with each of the three meals (120 g fat/day)
Number of subjects: 30
Study: 30642738

Group type: EXPERIMENTAL
Intervention: Oral citrulline supplementation (0.18 g/kg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Iso-nitrogenous placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral citrulline supplementation
Number of subjects: 9
Study: 28600758

Group type: EXPERIMENTAL
Intervention: Pessary treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Prolapse surgery
Number of subjects: 113
Study: 27524680

Group type: EXPERIMENTAL
Intervention: Intravenous morphine titration
Number of subjects: 293

Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 293
Study: 24295507

Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Attention control task
Number of subjects: 136
Study: 22525372

Group type: EXPERIMENTAL
Intervention: Houttuyninum (5.52 μg/ml IC50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Houttuyninum (in vivo administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Houttuyninum (40 μg/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Houttuyninum
Number of subjects: 0
Study: 19460169

Group type: EXPERIMENTAL
Intervention: Manual therapy directed to the talocrural joint
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 17529847

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d orally)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16002037

Group type: EXPERIMENTAL
Intervention: Contingency management intervention with family activities (N=29)
Number of subjects: 159

Group type: COMPARATOR
Intervention: No family activities (N=130)
Number of subjects: 159
Study: 15832486

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 265

Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 265
Study: 10435732

Group type: EXPERIMENTAL
Intervention: IgA-IgG
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7624915

Group type: EXPERIMENTAL
Intervention: N‐SIM (300 mg single dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: N‐SIM
Number of subjects: 16
Study: 2190516

Group type: EXPERIMENTAL
Intervention: Erythromycin, 500 mg, four times daily for 3 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 77
Study: 38695

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.010 to 0.020 mg/kg
Number of subjects: 0
Study: 30672793

Group type: EXPERIMENTAL
Intervention: Partial Mesh Excision (PME)
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Complete Mesh Excision (CME)
Number of subjects: 1904
Study: 30455090

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126
Study: 28526394

Group type: EXPERIMENTAL
Intervention: Intervention group (n=11,483)
Number of subjects: 58505

Group type: COMPARATOR
Intervention: Control group (n=47,122)
Number of subjects: 58505
Study: 25926146

Group type: EXPERIMENTAL
Intervention: Restrictive red blood cell (RBC) transfusion thresholds
Number of subjects: 936

Group type: COMPARATOR
Intervention: Liberal red blood cell (RBC) transfusion thresholds
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Postdischarge healthcare costs
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Annual initial in-hospital treatment cost for all AUGIB cases in the UK
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Incremental costs of treating hospitalised patients developing AUGIB
Number of subjects: 936
Study: 23340242

Group type: EXPERIMENTAL
Intervention: Dietary Fat Quality Assessment (DFQA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Food frequency questionnaire
Number of subjects: 120
Study: 21407248

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) for 3 months and dietary counselling at discharge
Number of subjects: 114

Group type: COMPARATOR
Intervention: Only dietary counselling at discharge (Control)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 114
Study: 18787937

Group type: EXPERIMENTAL
Intervention: Extinction of over-selected stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral control by previously over-selected stimulus extinguished
Number of subjects: 0
Study: 17353582

Group type: EXPERIMENTAL
Intervention: Neptune Krill Oil (NKO) 300 mg daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15492322

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 1439

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 1439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1439
Study: 11951578

Group type: EXPERIMENTAL
Intervention: Neuramide (N) administered intramuscularly twice daily for 28 days
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Neuramide (N)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Neuramide (N) and Placebo (P)
Number of subjects: 92
Study: 9517372

Group type: COMPARATOR
Intervention: Terbutaline (10 to 30 microg min(‐1))
Number of subjects: 6
Study: 8039194

Group type: EXPERIMENTAL
Intervention: Group A (30 patients) operated on without preoperative [18F]FDG/PET
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Group B (37 patients) operated on with FDG uptake in segments with wall motion abnormalities
Number of subjects: 74

Group type: COMPARATOR
Intervention: Group C (7 patients) with no FDG uptake, who were excluded from coronary surgery
Number of subjects: 74
Study: 3377230

Group type: EXPERIMENTAL
Intervention: Maximal warming (warm room, humidified respiratory gases, and warm intravenous fluids)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard temperature management (no special warming measures)
Number of subjects: 10
Study: 31167512

Group type: EXPERIMENTAL
Intervention: Bergamot polyphenol extract complex (BPE‐C) 650 mg daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bergamot polyphenol extract complex (BPE‐C) 1300 mg daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 27846629

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Balloon (DEB) after Cutting Balloon (CB) dilation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Drug-Eluting Stent (DES) implantation alone
Number of subjects: 120
Study: 25791668

Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT) - medical therapy plus psychotherapy (8 group and 2 individual sessions)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional treatment (CT) - medical therapy alone
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT) - medical therapy plus psychotherapy
Number of subjects: 158
Study: 23571784

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% (2 × 250 ml for 3 days postoperatively)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Saline solution 0.9% (control group)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6%
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% and Saline solution 0.9%
Number of subjects: 334
Study: 21963127

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (15, 30 or 60μg/kg daily)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 19819787

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Metoprolol 50 mg daily
Number of subjects: 38
Study: 16706303

Group type: EXPERIMENTAL
Intervention: Resin coating with RZ (RZII)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resin coating with SE/PLF (Clearfil SE Bond and Protect Liner F)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no resin coating)
Number of subjects: 36
Study: 15051198

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 500

Group type: COMPARATOR
Intervention: ECCE
Number of subjects: 500
Study: 11709433

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 9670411

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0